BRIEF-Compass Pathways Announces Dosing Complete For All Participants In Part A Of Phase 3 Comp005 Trial Of Comp360 Psilocybin

Reuters
Yesterday
BRIEF-Compass Pathways Announces Dosing Complete For All Participants In Part A Of Phase 3 Comp005 Trial Of Comp360 Psilocybin

April 22 (Reuters) - Compass Pathways PLC CMPS.O:

  • COMPASS PATHWAYS ANNOUNCES DOSING COMPLETE FOR ALL PARTICIPANTS IN PART A OF PHASE 3 COMP005 TRIAL OF COMP360 PSILOCYBIN FOR TREATMENT-RESISTANT DEPRESSION

  • COMPASS PATHWAYS PLC - TOP-LINE 6-WEEK PRIMARY ENDPOINT RESULTS EXPECTED IN LATE JUNE

Source text: ID:nBw31H0b6a

Further company coverage: CMPS.O

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10